Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase 1, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-1010 (IL12-FHAB) in Adult Patients With Advanced Solid Tumors.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05352750
• Other study ID #: SB101
• Status: Recruiting
• Phase: Phase 1
• Start date: April 20, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: July 2023
• Source: Sonnet BioTherapeutics
• Contact: Manuel DaFonseca
• Phone: 1-609-451-3900
• Email: clinical[@]sonnetbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.

Description:

This is a study of SON-1010, a single-chain human Interleukin-12 (IL12) cytokine linked to a single-chain variable region (scFv) antibody fragment, known as the fully human albumin binding domain (FHAB). The albumin binding domain moiety of SON-1010 attaches to albumin in the bloodstream, resulting in significantly enhanced drug PK properties, potentially lower risk than IL12 alone, and a broader therapeutic index. The study is designed to safely and rapidly establish the Recommended Phase 2 Dose (RP2D) and/or maximum tolerated dose (MTD) with up to 5 dose-escalation groups and to expand the dataset at the recommended RP2D.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: December 31, 2024
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18 at the time of informed consent

2. Must have histologically or cytologically verified solid epithelial or mesenchymal tumors.

3. Locally advanced or metastatic disease

4. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or the modified criteria for immune-based therapeutics (termed iRECIST) as appropriate. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

5. Must have been treated with standard of care therapies for their disease and have no standard alternative treatment options that are deemed by the treating physician to offer reasonable or potentially better benefit, or not be a candidate for standard therapy for their disease due to an underlying physical condition. Note that if patients have alternative therapies available that are known to confer clinical benefit, they should be informed of these therapies during the informed consent process.

6. Must weigh >50 kg to =120 kg at screening (to facilitate SON-1010 dilution before dosing).

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

8. Adequate organ and bone marrow function, in the absence of growth factors, as defined

by the following laboratory parameters by day -1:

1. Hematologic: neutrophils =1500/µL, platelets =100,000/µL, lymphocytes =500/µL, hemoglobin =9 g/dL (transfusion and/or erythropoietin not permitted within 2 weeks before blood draw)

2. Renal: estimated glomerular filtration rate =45 mL/min/1.73 m2 (Levey 2009)

3. Hepatic: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5 x ULN or =5 x ULN if liver metastases; coagulation international normalized ratio (INR) and activated partial thromboplastin time (aPTT), =1.5 x ULN; serum total bilirubin =1.5 x ULN or total bilirubin =ULN for patients with total bilirubin >1.5 x ULN (except for elevated bilirubin secondary to Gilberts disease. Confirmation of Gilberts diagnosis requires: elevated unconjugated (indirect) bilirubin values; normal complete blood count (in previous 12 months), blood smear and reticulocyte count; normal transaminases and alkaline phosphatase in previous 12 months.

4. Chemistry: albumin =3.0 g/dL at screening

9. Females of childbearing potential, <1-year postmenopause who are not permanently sterile, must have a negative serum pregnancy test (beta-human chorionic gonadotropin [ß-HCG]) at baseline (unless they have had a hysterectomy), and agree to use 2 highly effective methods of birth control during the study and for 30 days after the last dose of study intervention. Females who are not of childbearing potential (have had a tubal ligation, hysterectomy, or bilateral oophorectomy, or are =1 year postmenopause) or have a partner who has had a vasectomy do not need to use any contraception. Nonchildbearing potential is defined as surgically sterile or postmenopausal (defined as 12 months of spontaneous amenorrhea). A follicle stimulating hormone (FSH) level >40 IU/L at screening will confirm postmenopausal status. If a patient is not sexually active, but becomes active, then she and her male partner must use 2 methods of adequate contraception.

10. Males and their female partners must use a highly effective method of birth control if female partner(s) is of childbearing potential and must not donate sperm during the study and for 30 days after the last dose of study intervention.

11. Willing and able to provide signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

12. Must be able to communicate well with Investigator and/or study site personnel and to comply with the requirements of the entire study.

Exclusion Criteria:

1. Known history of allergy to any component of study intervention.

2. History of severe allergic/anaphylactic reaction.

3. Infection with HIV-1 or HIV-2 or a history of Kaposi sarcoma and/or Multicentric Castleman Disease.

4. Current active liver disease from any cause, including hepatitis A (hepatitis A virus IgM positive), hepatitis B (hepatitis B virus [HBV] surface antigen positive), or hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic acid). Patients with HCV with undetectable virus after treatment are eligible (note: patients must have completed curative antiviral therapy at least 4 weeks before screening).

5. Pregnancy and/or lactation

6. Has received a live or live-attenuated vaccine within 28 days before the first dose of study intervention. Note: Administration of killed vaccines and COVID-19 vaccines that are not live or live-attenuated are allowed if >14 days before the first dose.

7. History of any active infection requiring systemic antibiotics, antivirals or antifungals within 14 days before the first dose of study intervention, including COVID-19 as determined by the currently recommended testing strategy for acute infection.

8. Any acute noninfectious illness not resolved by14 days before day 1.

9. History of or known or suspected autoimmune disease (exception(s): patients with vitiligo, Type I diabetes, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at Screening are allowed). Other exceptions may be allowed following discussion with the Sponsor Medical Monitor for patients who have not received treatment for their autoimmune disorder in the past 3 years.

10. Known active central nervous system metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks before study entry and have no evidence of new or enlarging brain metastases.

11. Unresolved toxicities from prior anticancer therapy, defined as not resolved to baseline or to grade 1 by the CTCAE V 5.0 criteria (NCI 2017) except for alopecia, peripheral neuropathy, and hypothyroidism secondary to prior checkpoint inhibitor therapy if currently being treated and clinically euthyroid.

12. Receipt of any investigational agent or treatment within a period of 5 half-lives (or 28 days whichever is shorter) before the first dose of study intervention.

13. Any prior immunotherapy or treatment with checkpoint inhibitors, unless approved by the Sponsor, within a period of 5 half-lives (or 3 months, whichever is shorter) since the last dose of the therapy.

14. Use of systemic steroids >10 mg/day prednisone (or equivalent) within 14 days of enrollment, except for local (topical, nasal, or inhaled) steroid use. Limited doses of systemic steroids (eg, in patients with exacerbation of reactive airway disease) must have been completed at least 10 days before enrollment. Steroid use to prevent IV contrast allergic reaction or anaphylaxis in patients who have known contrast allergies is allowed at any time before enrollment.

15. Active known second malignancy except any of the following:

• Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or Stage 0 carcinoma in situ
• Adequately treated Stage I cancer from which the patient is currently in remission and has been in remission for =2 years
• Low-risk prostate cancer with Gleason score <7 and prostate-specific antigen <10 ng/mL
• Any other cancer from which the patient has been disease-free for =2 years

16. Use of biotin (ie Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 µg (FDA 2019) (Note: patients who switch from a high dose to a dose of 30 µg/day or less are eligible).

17. Any of the following events within 6 months before baseline Day 1:

• Myocardial infarction
• Unstable angina
• Unstable symptomatic ischemic heart disease
• New York Heart Association class III or IV heart failure
• Thromboembolic events (eg, pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, or severe congenital heart disease)

18. Electrocardiogram QT interval corrected for heart rate (QTc) > 470 msec, measured by Fridericia's formula [QTcF=QT/(RR0.33)]. If the QTc is prolonged in a patient with a pacemaker or bundle branch block, the patient may be enrolled in the study if confirmed by the medical monitor.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Biological:
• SON-1010
SON-1010 multiple ascending dose

Locations

Country	Name	City	State
United States	Sarcoma Oncology Center	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
Sonnet BioTherapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety and tolerability of SON-1010	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	Through study completion, an average of 1 year
Primary	To establish the maximum tolerated dose (MTD) of SON-1010	Highest safe dose achieved during dose escalation	Through study completion, an average of 1 year
Primary	To establish the recommended Phase 2 dose (RP2D) of SON-1010	Highest safe dose achieved during dose escalation	Through study completion, an average of 1 year
Secondary	Serum and urine concentrations of SON-1010 will be determined at various time points	Concentration vs time of SON-1010 will be measured using blood & urine samples taken at various time points on study	Cycles 1 and 2 (each cycle is 28 days)
Secondary	Effect of SON-1010 on Serum cytokine levels	Concentration of serum level of IL-2, IL-6, IL-10 will be measured using blood samples taken at various time points on study	Cycles 1 and 2 (each cycle is 28 days)
Secondary	Evaluation of SON-1010 immunogenicity	Evaluate the immunogenicity of SON-1010 by measuring the number of patients developing anti-SON-1010 antibodies	Cycles 1, 2 and 3 (each cycle is 28 days)
Secondary	To assess the antitumor activity of SON-1010	Objective response rate per RECIST 1.1 and iRECIST or other appropriate disease-specific response criteria.	Through study completion, an average of 1 year